Zevra Q1 net loss $16.6M; OLPRUVA launch with 4 patients, cash runway into 2026

ZEVRA THERAPEUTICS, INC.

Net loss of $16.6M ($0.40 loss per share) compared to $13.2M loss in Q1 2023.
Revenue $3.4M, including $2.2M French arimoclomol EAP reimbursement and $1.2M AZSTARYS royalties.
OLPRUVA commercial launch: 4 patient enrollments, ~75% covered lives as of May 1, 2024.
Arimoclomol NDA PDUFA date set for September 21, 2024; KP1077 positive Phase 2 IH data.
Debt refinancing with up to $100M; $60M drawn, net $14M added to cash; runway extends into 2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ZEVRA THERAPEUTICS, INC. reported first quarter ended March 31, 2024 results: revenue $3.4 million, net income ($16.6) million, EPS ($0.40) per basic and diluted share.

Period: first quarter ended March 31, 2024
Revenue: $3.4 million
Net income: ($16.6) million
EPS: ($0.40) per basic and diluted share
Result: reported results

Exact text from the filing

patients currently enrolled and to preserve the value of the program while conducting our portfolio review. Overview of Q1 2024 Financial Results: Net revenue for Q1 2024 was $3.4 million, compared to net revenue of $3.2 million in Q1 2023. The components of revenue during the first quarter included $2.2 million in net reimbursements from the French EAP for

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

ZEVRA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-24-015210

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.